DK3553084T3 - Anti-adrenomedullin (adm)-antistof eller anti-adm-antistoffragment eller anti-adm-non-ig-scaffold til forebyggelse eller reduktion af organdysfunktion eller organsvigt hos en patient med en kronisk eller akut sygdom eller akut tilstand - Google Patents

Anti-adrenomedullin (adm)-antistof eller anti-adm-antistoffragment eller anti-adm-non-ig-scaffold til forebyggelse eller reduktion af organdysfunktion eller organsvigt hos en patient med en kronisk eller akut sygdom eller akut tilstand Download PDF

Info

Publication number: DK3553084T3
Authority: DK; Denmark
Prior art keywords: adm; acute; istoffragment; adrenomedullin; scaffold
Prior art date: 2011-11-16

Application number

DK19162009.5T

Other languages

English (en)

Inventor

Andreas Bergmann

Original Assignee

Adrenomed Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-16

Filing date

2012-11-16

Publication date

2023-02-20

2012-11-16 Application filed by Adrenomed Ag filed Critical Adrenomed Ag

2023-02-20 Application granted granted Critical

2023-02-20 Publication of DK3553084T3 publication Critical patent/DK3553084T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001144—Hormones, e.g. calcitonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Hematology (AREA)
Diabetes (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Communicable Diseases (AREA)
Zoology (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Pathology (AREA)

DK19162009.5T 2011-11-16 2012-11-16 Anti-adrenomedullin (adm)-antistof eller anti-adm-antistoffragment eller anti-adm-non-ig-scaffold til forebyggelse eller reduktion af organdysfunktion eller organsvigt hos en patient med en kronisk eller akut sygdom eller akut tilstand DK3553084T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP11189447		2011-11-16
EP12160014		2012-03-16
EP12784631.9A EP2780369B1 (en)	2011-11-16	2012-11-16	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition

Publications (1)

Publication Number	Publication Date
DK3553084T3 true DK3553084T3 (da)	2023-02-20

Family

ID=48429015

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK12784631.9T DK2780369T3 (da)	2011-11-16	2012-11-16	Anti-adrenomedullin (adm)-antistof eller anti-adm-antistoffragment eller anti-adm-non-ig-scaffold til forebyggelse eller reduktion af organdysfunktion eller organsvigt hos en patient med en kronisk eller akut sygdom eller akut tilstand
DK19162009.5T DK3553084T3 (da)	2011-11-16	2012-11-16	Anti-adrenomedullin (adm)-antistof eller anti-adm-antistoffragment eller anti-adm-non-ig-scaffold til forebyggelse eller reduktion af organdysfunktion eller organsvigt hos en patient med en kronisk eller akut sygdom eller akut tilstand

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK12784631.9T DK2780369T3 (da)	2011-11-16	2012-11-16	Anti-adrenomedullin (adm)-antistof eller anti-adm-antistoffragment eller anti-adm-non-ig-scaffold til forebyggelse eller reduktion af organdysfunktion eller organsvigt hos en patient med en kronisk eller akut sygdom eller akut tilstand

Country Status (18)

Country	Link
US (5)	US20140328853A1 (da)
EP (3)	EP3553084B1 (da)
JP (2)	JP6193871B2 (da)
AU (1)	AU2012338731B2 (da)
DK (2)	DK2780369T3 (da)
ES (2)	ES2729710T3 (da)
FI (1)	FI3553084T3 (da)
HR (2)	HRP20230146T1 (da)
HU (2)	HUE044383T2 (da)
LT (2)	LT2780369T (da)
NZ (1)	NZ624873A (da)
PL (2)	PL3553084T3 (da)
PT (2)	PT2780369T (da)
RS (2)	RS58880B1 (da)
SG (3)	SG10201801919QA (da)
SI (1)	SI3553084T1 (da)
WO (1)	WO2013072511A1 (da)
ZA (2)	ZA201403552B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10793626B2 (en) *	2013-12-20	2020-10-06	Angiobiomed Gmbh	Adrenomedullin binder for use in therapy of cancer
EP3339324A1 (en)	2016-12-22	2018-06-27	sphingotec GmbH	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
KR20190120174A (ko)	2016-12-16	2019-10-23	아드레노메드 아게	울혈의 중재 및 치료가 필요한 환자에서 울혈의 중재 및 치료에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드
US20220227854A1 (en) *	2017-09-25	2022-07-21	Adrenomed Ag	Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
MX2020004072A (es)	2017-10-18	2020-07-28	Adrenomed Ag	Monitoreo de terapia bajo tratamiento con un aglutinante anti-adrenomodulina (adm).
EP3871689A1 (en)	2020-02-26	2021-09-01	sphingotec GmbH	Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
CN115244401A (zh)	2020-02-27	2022-10-25	4Teen4制药有限公司	用于在休克患者中进行nt-adm抗体的治疗指导、监测和分层的dpp3
CA3168978A1 (en) *	2020-02-27	2021-09-02	Andreas Bergmann	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
CN115244081A (zh)	2020-02-27	2022-10-25	艾德里诺医药公司	用于治疗休克患者的抗肾上腺髓质素(adm)结合剂
US20210285949A1 (en) *	2020-03-16	2021-09-16	Sphingotec Gmbh	Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
CN111627559B (zh) *	2020-06-17	2023-08-29	北京大学第三医院（北京大学第三临床医学院）	预测患者死亡风险的系统
CN119072492A (zh)	2022-03-15	2024-12-03	艾德里诺医药公司	抗肾上腺髓质素（adm）抗体或抗adm抗体片段的稳定水性制剂
KR20250040987A (ko) *	2022-07-20	2025-03-25	상하이 제유 파마슈티칼 컴퍼니 리미티드	항-아드레노메둘린 비중화 항체, 이의 제조 방법 및 응용
US20260028423A1 (en)	2022-07-29	2026-01-29	4TEEN4 Pharmaceuticals GmbH	Prediction of an increase of dpp3 in a patient with septic shock
IL318667A (en)	2022-07-29	2025-03-01	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
KR20260034620A (ko) *	2023-05-05	2026-03-11	페록시테크 인코포레이티드.	패혈성 쇼크 치료용 조성물 및 방법
WO2026046978A1 (en)	2024-08-26	2026-03-05	Pam Theragnostics Gmbh	Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU634716B2 (en)	1988-08-01	1993-03-04	Ciba Corning Diagnostics Corp.	Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
EP1690935A3 (en)	1990-01-12	2008-07-30	Abgenix, Inc.	Generation of xenogeneic antibodies
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
ES2139598T3 (es)	1990-07-10	2000-02-16	Medical Res Council	Procedimientos para la produccion de miembros de parejas de union especifica.
JPH07503132A (ja)	1991-12-17	1995-04-06	ジェンファーム　インターナショナル，インコーポレイティド	異種抗体を産生することができるトランスジェニック非ヒト動物
JP2774769B2 (ja)	1993-04-26	1998-07-09	賢治寒川	アドレノメデュリン
WO1997007214A1 (en) *	1995-08-18	1997-02-27	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology
CA2242308A1 (en)	1997-12-08	1999-06-08	Smithkline Beecham Laboratoires Pharmaceutiques	Novel compounds
DE19847690A1 (de)	1998-10-15	2000-04-20	Brahms Diagnostica Gmbh	Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
US6818418B1 (en)	1998-12-10	2004-11-16	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
EP1214600B1 (en) *	1999-09-10	2005-12-21	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Determination of adrenomedullin-binding proteins
EP1322957B1 (en)	2001-05-04	2009-08-12	Biosite Incorporated	Diagnostic markers of acute coronary syndromes and methods of use thereof
CN1628126A (zh)	2001-08-30	2005-06-15	比奥雷克西斯药物公司	经修饰的运铁蛋白融合蛋白
US6864237B2 (en)	2002-05-17	2005-03-08	Ping Wang	Treatment of shock using adrenomedullin and adrenomedullin binding protein-1
PT2298278E (pt)	2002-06-07	2016-02-25	Dyax Corp	Prevenção e redução da perda de sangue e resposta inflamatória
DE10316583A1 (de)	2003-04-10	2004-10-28	B.R.A.H.M.S Aktiengesellschaft	Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
WO2004097423A1 (en)	2003-04-25	2004-11-11	Genova Ltd.	Secreted polypeptide species reduced cardiovascular disorders
US6884781B2 (en)	2003-05-16	2005-04-26	Ping Wang	Treatment of shock using adrenomedullin binding protein-1
CA2543360A1 (en)	2003-10-24	2005-05-06	Joost A. Kolkman	Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en)	2004-02-23	2010-02-04	Anaphore, Inc.	Tetranectin Trimerizing Polypeptides
US20070280886A1 (en)	2004-09-09	2007-12-06	Bayer Healthcare Ag	Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr)
AU2005287557B2 (en)	2004-09-21	2011-10-13	Biontech Ag	Use of microproteins as tryptase inhibitors
JP4976412B2 (ja)	2005-12-01	2012-07-18	ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー	エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法
US7825217B2 (en)	2006-09-15	2010-11-02	University Of Kansas Medical Center	Polypeptides for bone mineralization
EP2215246B1 (en) *	2007-10-31	2015-01-07	MedImmune, LLC	Protein scaffolds
ES2373832T3 (es)	2007-12-19	2012-02-09	Affibody Ab	Polipéptido derivado de proteína a y capaz de unirse a pdgf.
NZ592591A (en)	2008-11-03	2012-04-27	Molecular Partners Ag	Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction
CA2772162C (en)	2009-08-27	2018-05-22	Covagen Ag	Anti-il-17a fynomers and medical uses thereof
BR112012014417B1 (pt)	2009-12-14	2021-11-09	Scil Proteins Gmbh	Proteínas ubiquitinas modificadas tendo uma atividade de ligação específica para o extradomínio b de fibronectina
DE102010040035A1 (de)	2010-03-04	2011-09-08	Robert Bosch Gmbh	Verbesserungen der Rückwärts-Analyse zur Bestimmung von Fehlermaskierungsfaktoren
AU2011263786B2 (en)	2010-06-08	2014-11-13	Astrazeneca Ab	Tear lipocalin muteins binding IL-4 R alpha
FR2964103B1 (fr)	2010-08-30	2018-11-23	Universite D'aix-Marseille	Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament
US9140696B2 (en)	2011-11-16	2015-09-22	Adrenomed Ag	Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition

2012
- 2012-11-16 PL PL19162009.5T patent/PL3553084T3/pl unknown
- 2012-11-16 LT LTEP12784631.9T patent/LT2780369T/lt unknown
- 2012-11-16 RS RS20190738A patent/RS58880B1/sr unknown
- 2012-11-16 DK DK12784631.9T patent/DK2780369T3/da active
- 2012-11-16 HR HRP20230146TT patent/HRP20230146T1/hr unknown
- 2012-11-16 JP JP2014541695A patent/JP6193871B2/ja active Active
- 2012-11-16 SI SI201232021T patent/SI3553084T1/sl unknown
- 2012-11-16 HU HUE12784631 patent/HUE044383T2/hu unknown
- 2012-11-16 AU AU2012338731A patent/AU2012338731B2/en active Active
- 2012-11-16 ES ES12784631T patent/ES2729710T3/es active Active
- 2012-11-16 EP EP19162009.5A patent/EP3553084B1/en active Active
- 2012-11-16 NZ NZ624873A patent/NZ624873A/en unknown
- 2012-11-16 PL PL12784631T patent/PL2780369T3/pl unknown
- 2012-11-16 SG SG10201801919QA patent/SG10201801919QA/en unknown
- 2012-11-16 HU HUE19162009A patent/HUE061696T2/hu unknown
- 2012-11-16 EP EP21216077.4A patent/EP4086283A1/en active Pending
- 2012-11-16 EP EP12784631.9A patent/EP2780369B1/en active Active
- 2012-11-16 FI FIEP19162009.5T patent/FI3553084T3/fi active
- 2012-11-16 DK DK19162009.5T patent/DK3553084T3/da active
- 2012-11-16 US US14/358,334 patent/US20140328853A1/en not_active Abandoned
- 2012-11-16 WO PCT/EP2012/072930 patent/WO2013072511A1/en not_active Ceased
- 2012-11-16 PT PT12784631T patent/PT2780369T/pt unknown
- 2012-11-16 RS RS20230115A patent/RS64060B1/sr unknown
- 2012-11-16 SG SG11201402366PA patent/SG11201402366PA/en unknown
- 2012-11-16 LT LTEP19162009.5T patent/LT3553084T/lt unknown
- 2012-11-16 ES ES19162009T patent/ES2938653T3/es active Active
- 2012-11-16 HR HRP20191010TT patent/HRP20191010T1/hr unknown
- 2012-11-16 PT PT191620095T patent/PT3553084T/pt unknown
- 2012-11-16 SG SG10202006318TA patent/SG10202006318TA/en unknown
2014
- 2014-05-15 ZA ZA2014/03552A patent/ZA201403552B/en unknown
2016
- 2016-02-16 US US15/044,474 patent/US10221238B2/en active Active
2017
- 2017-05-17 JP JP2017098527A patent/JP2017155051A/ja active Pending
2018
- 2018-09-20 US US16/136,892 patent/US10800842B2/en active Active
- 2018-12-10 US US16/214,963 patent/US11673949B2/en active Active
2019
- 2019-09-30 ZA ZA2019/06427A patent/ZA201906427B/en unknown
2023
- 2023-05-02 US US18/142,070 patent/US12338281B2/en active Active

Also Published As

Publication number	Publication date
AU2012338731B2 (en)	2017-07-06
US20190092857A1 (en)	2019-03-28
LT2780369T (lt)	2019-07-10
ZA201403552B (en)	2024-06-26
EP3553084A1 (en)	2019-10-16
JP2015501797A (ja)	2015-01-19
HUE061696T2 (hu)	2023-08-28
US20190010226A1 (en)	2019-01-10
DK2780369T3 (da)	2019-06-17
LT3553084T (lt)	2023-03-10
SG10201801919QA (en)	2018-04-27
PT3553084T (pt)	2023-02-17
JP2017155051A (ja)	2017-09-07
ZA201906427B (en)	2020-08-26
RS58880B1 (sr)	2019-08-30
HRP20230146T1 (hr)	2023-04-28
ES2938653T3 (es)	2023-04-13
US20140328853A1 (en)	2014-11-06
SG11201402366PA (en)	2014-06-27
PT2780369T (pt)	2019-06-18
US20160176960A1 (en)	2016-06-23
WO2013072511A1 (en)	2013-05-23
ES2729710T3 (es)	2019-11-05
SI3553084T1 (sl)	2023-05-31
PL2780369T3 (pl)	2019-09-30
NZ624873A (en)	2016-07-29
US12338281B2 (en)	2025-06-24
HUE044383T2 (hu)	2019-10-28
US10800842B2 (en)	2020-10-13
FI3553084T3 (fi)	2023-03-03
EP3553084B1 (en)	2022-11-16
EP2780369B1 (en)	2019-03-13
PL3553084T3 (pl)	2023-04-17
US10221238B2 (en)	2019-03-05
US11673949B2 (en)	2023-06-13
AU2012338731A1 (en)	2014-05-29
US20240368268A1 (en)	2024-11-07
EP4086283A1 (en)	2022-11-09
EP2780369A1 (en)	2014-09-24
RS64060B1 (sr)	2023-04-28
SG10202006318TA (en)	2020-08-28
JP6193871B2 (ja)	2017-09-06
HRP20191010T1 (hr)	2019-08-23

Publication	Publication Date	Title
DK2780369T3 (da)	2019-06-17	Anti-adrenomedullin (adm)-antistof eller anti-adm-antistoffragment eller anti-adm-non-ig-scaffold til forebyggelse eller reduktion af organdysfunktion eller organsvigt hos en patient med en kronisk eller akut sygdom eller akut tilstand
NO2021033I1 (no)	2021-09-06	Selineksor eller et farmasøytisk akseptabelt salt derav
NO2020037I1 (no)	2020-11-16	alpelisib eller et farmasøytisk akseptabelt salt derav
DK2594587T3 (da)	2014-07-21	Anti-Adrenomedullin (ADM)-antistof eller anti-ADM-antistoffragment eller anti-ADM ikke-Ig-protein-scaffold til at reducere risikoen for mortalitet hos en patient med en kronisk eller akut sygdom eller akut tilstand
NO2019024I1 (no)	2019-05-20	Brigatinib eller et farmasøytisk akseptabelt salt derav
NO2017059I1 (no)	2017-11-13	ribosiklib eller et farmasøytisk akseptabelt salt derav
DK2452281T3 (da)	2020-01-13	Fremgangsmåde til at forudsige virkningen af lægemidler i en patient
EP2774753A4 (en)	2015-06-03	MULTILAYER STRUCTURE
DK2555710T3 (da)	2019-10-07	Transkateterafgivelsessystem til prostetisk hjerteventil med genindfangningsegenskab
ZA201403550B (en)	2021-05-26	Anti-adrenomedullin (adm) antibody of anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
EP2894267A4 (en)	2016-07-06	FLUSH
DK3276004T3 (da)	2020-04-06	Fremgangsmåder til behandling af kronisk nyresygdom
EP2766107A4 (en)	2015-07-08	MULTILAYER POROUS COMPOSITE
DK2594588T3 (da)	2014-07-21	Anti-Adrenomedullin (ADM)-antistof eller anti-ADM-antistoffragment eller anti-ADM-ikke-Ig-protein-scaffold til anvendelse i terapi
EP2681370A4 (en)	2014-11-19	BIDET WITH MULTIPLE SPRAYING FUNCTIONS
EP2702310A4 (en)	2015-08-05	PRISM-CONTAINED PRESSURE RESERVOIR WITH GRILLE STRUCTURE
EP2663266C0 (en)	2025-02-12	ENDOPROSTHESIS
FR2982524B1 (fr)	2013-12-27	Structure multicouche
PT2772261T (pt)	2018-01-08	Adsorvente administrado oralmente
EP2770969A4 (en)	2015-07-22	Bed chair
EP2744658A4 (en)	2015-04-22	MULTILAYER POLYMER STRUCTURES
DK2667895T3 (da)	2019-06-11	Anvendelse af mindst en p75ntr-receptor-inhibitor, alene eller i forbindelse med mindst en trka-receptor-aktivator, eller af mindst en trka-receptor-aktivator til behandling af kroniske inflammatoriske sygdomme
BR112013029369A2 (pt)	2017-01-31	laminado de reforço tendo uma característica de alinhamento
EP2373306A4 (en)	2012-05-30	TRANSDERMAL APPOINTED ALISKIRES
FIU20114005U0 (fi)	2011-04-20	Vesilukkojärjestely